Hemostasis and Circulation pp 115-120 | Cite as
Cathepsin B Efficiently Activets the Soluble and the Tumor Cell Receptor-Bound Form of the Proenzyme Urokinase-Type Plasminogen Activator (Pro-Upa)
Abstract
Tumor cell invasion and metastasis is a multifactorial process, which at each step may require the action, of proteolytic enzymes such as collagenase, cathepsins, plasmin, or plasminogen activators 1,2. An enzymatically inactive proenzyme form of the urokinase-type plasminogen activator (pro-uPA) is secreted by tumor cells 1,3. Cathepsin B, a cysteine-dependent protease, which is elevated in tumors, plays a regulatory role in collagen degradation, since it can convert inactive procollagenase IV to its enzymatically active form 4. We demonstrate that cathepsin B has the capacity to efficiently convert soluble or tumor cell receptor-bound pro-uPA to enzymatically active two-chain uPA. Thus, the cellular protease cathepsin B may substitute for the plasma protease plasmin in the activation of pro-uPA released by tumor cells.
Keywords
Plasminogen Activator U937 Cell Tumor Cell Surface Previous Biochemical Study Tumor Cell ReceptorPreview
Unable to display preview. Download preview PDF.
References
- 1.Dano K., Atrdreasen P.A., Grondahl-Hansen J., Kristensen P.I., Nielsen L.S. and Striver L. (1985) Adv. Cancer Res. 44: 139–226.PubMedCrossRefGoogle Scholar
- 2.Liotta L.A., Rao C.N. and Barsky S.U. (1983) Lab. Invest. 491: 636–649.Google Scholar
- 3.Stoppelli M.P., Corti A., Soffientini A., Cassani G., Blasi F. and Assoian R.K. (1985) Proc. Natl. Acad. Sei. USA 82: 4939–4943.CrossRefGoogle Scholar
- 4.Eeckhout Y. and Vaes G. (1977) Biochem. J. 166 21–31.PubMedGoogle Scholar
- 5.Estreicher A., Wohlwend A., Belin D., Schleuning W.D. and Vassalli J.D. (1989) J. Biol. Chem. 264: 1180–1189.PubMedGoogle Scholar
- 6.Laemmli U.K. (1970) Nature 227 680–685.PubMedCrossRefGoogle Scholar
- 7.Schmitt M., Kanayama N., Henschen A., Hollrider A., Hafter R., Gulba D., Janicke F. and Graeff H. (1989) FEBS Lett. 255: 83–88.PubMedCrossRefGoogle Scholar
- 8.Ichinose A., Fujikawa K. and Suyama T. (1986) J. Biol. Chem. 261: 3486–3489.PubMedGoogle Scholar
- 9.Gurewich V. and Pannell R. (1987) Blood 69: 969–972.Google Scholar
- 10.Krepela E., Bartek J., Skalkova D., Vicar J., Rasnick D., Taylor-Papadimit-riou J. and Hallowes R.C. (1987) J. Cell Sci. 87: 145–154.PubMedGoogle Scholar
- 11.Nishimura Y. and Kato K. (1987) Biochem. Biophys. Res. Commun. 148: 254–259.PubMedCrossRefGoogle Scholar
- 12.Tandon A.T., Clark G.M., Chamness G.C., Chirgwin J.M. and McGuire W.L. (1990) New Engl. J. Med. 322: 297–302.PubMedCrossRefGoogle Scholar
- 13.Markus G. (1988) Enzyme (Basel) 40: 158–172.Google Scholar
- 14.Janicke F., Schmitt M., Ulm K., Gossner W. and Graeff II. (1989) Lancet 11: 1149.Google Scholar
- 15.Duffy M., O’Grady P., Devaney D., O’Siorain L., Fennelly J.J. and Lijnen H.R. (1988) Cancer 62: 531–533.PubMedCrossRefGoogle Scholar
- 16.Lijnen H.R., Van Hoef B., Nelles L. and Collen D. (1990) J. Biol. Chem. 265: 5232–5236.PubMedGoogle Scholar